Tags » Renal Cell Carcinoma
San Francisco-based drug discovery company Exelixis is to collaborate with Japanese pharma giant Takeda in the development of Exelixis’ lead cancer candidate cabozantinib.
Cabozantinib is a tyrosine kinase inhibitor for both c-Met and VEGFR2 molecules, both of which have been shown to have key roles in tumour growth, metastasis, and angiogenesis (the formation of new blood vessels). 329 more words
Silencing communication pathways between cancer cells could help prevent tumour growth, according to new findings.
The study, carried out by researchers at the Barts Cancer Institute, found that by blocking a molecule called CCR4 – a protein known to be over-expressed in several types of cancer – led to a reduction in tumour growth. 116 more words